Cellectis S.A.
CLLS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 110.3% | 57% | -16.2% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 93.3% | 85.5% | 81.1% | 80.2% |
| EBITDA | $0 | -$0 | -$0 | $0 |
| % Margin | 21.9% | -99.6% | -105.9% | 111.5% |
| Net Income | $0 | -$0 | -$0 | $0 |
| % Margin | 1.7% | -141.9% | -170.1% | 46.6% |
| EPS Diluted | 0.006 | -0.24 | -0.18 | 0.059 |
| % Growth | 102.5% | -33.3% | -404.1% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |